current affair
The Phase-III trial Efficacy and Safety data of COVAXIN got published in the prestigious medical journal The Lancet. The safety profile of Bharat Biotech’s COVAXIN has now been well-established, it showed 77.8 per cent efficacy against symptomatic COVID-19.
from Jagran Josh https://ift.tt/3wJej0R
via IFTTT
Post a Comment